Terms: = Brain cancer AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Treatment
107 results:
1. Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma.
Swellam M; Khalifa MK; Nageeb AM; Ezz El-Arab L; El-Mahdy M; El-Bahy K; Sayed Mahmoud M
Int J Immunopathol Pharmacol; 2024; 38():3946320241250294. PubMed ID: 38686946
[TBL] [Abstract] [Full Text] [Related]
2. Partial Response to Naxitamab for brain Metastasis in Neuroblastoma.
Onyeukwu C; Williams A; Seyboth B; Muñoz L; Scaria G; Kent P
J Pediatr Hematol Oncol; 2024 Mar; 46(2):e188-e190. PubMed ID: 38189408
[TBL] [Abstract] [Full Text] [Related]
3. Comparative Analysis of the Embryonal brain Tumors Based on Their Molecular Features.
Shcherbina V; Kovalevska L; Pedachenko E; Malysheva T; Kashuba E
Discov Med; 2023 Oct; 35(178):733-749. PubMed ID: 37811612
[TBL] [Abstract] [Full Text] [Related]
4. The evolution of spinal cord surgery: history, people, instruments, and results.
Shimony N; Fehnel K; Abbott IR; Jallo GI
Childs Nerv Syst; 2023 Oct; 39(10):2687-2700. PubMed ID: 37658937
[TBL] [Abstract] [Full Text] [Related]
5. Serum brain-derived neurotrophic factor (BDNF) as predictors of childhood neuroblastoma relapse.
Xiong X; Zeng M; Peng X; Feng C; Li C; Weng W; Li Y
BMC Cancer; 2023 Jul; 23(1):670. PubMed ID: 37460933
[TBL] [Abstract] [Full Text] [Related]
6. Pediatric Precision Medicine at the National cancer Center Japan: Prospective Genomic Study of Pediatric Patients with cancer as Part of the TOP-GEAR Project.
Tao K; Yamazaki F; Kubo T; Sunami K; Kumamoto T; Arakawa A; Sugiyama M; Watanabe Y; Nakajima M; Shirakawa N; Tanimura K; Koyama T; Hirata M; Sudo K; Tanabe N; Watanabe T; Yoshida T; Kitami M; Yoshida A; Yatabe Y; Nakano Y; Ohira M; Kamijo T; Nakazawa A; Kato M; Ichimura K; Kohno T; Yamamoto N; Hishiki T; Ichikawa H; Ogawa C
JCO Precis Oncol; 2023 Jul; 7():e2200266. PubMed ID: 37410973
[TBL] [Abstract] [Full Text] [Related]
7. Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles.
Massimino M; Vennarini S; Buttarelli FR; Antonelli M; Colombo F; Minasi S; Pecori E; Ferroli P; Giussani C; Schiariti M; Schiavello E; Biassoni V; Erbetta A; Chiapparini L; Nigro O; Boschetti L; Gianno F; Miele E; Modena P; De Cecco L; Pollo B; Barretta F
J Neurooncol; 2023 Jul; 163(3):577-586. PubMed ID: 37326761
[TBL] [Abstract] [Full Text] [Related]
8. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.
Goddard J; Castle J; Southworth E; Fletcher A; Crosier S; Martin-Guerrero I; García-Ariza M; Navajas A; Masliah-Planchon J; Bourdeaut F; Dufour C; Ayrault O; Goschzik T; Pietsch T; Sill M; Pfister SM; Rutkowski S; Richardson S; Hill RM; Williamson D; Bailey S; Schwalbe EC; Clifford SC; Hicks D
Acta Neuropathol; 2023 May; 145(5):651-666. PubMed ID: 37014508
[TBL] [Abstract] [Full Text] [Related]
9. ARF suppression by MYC but not mycn confers increased malignancy of aggressive pediatric brain tumors.
Mainwaring OJ; Weishaupt H; Zhao M; Rosén G; Borgenvik A; Breinschmid L; Verbaan AD; Richardson S; Thompson D; Clifford SC; Hill RM; Annusver K; Sundström A; Holmberg KO; Kasper M; Hutter S; Swartling FJ
Nat Commun; 2023 Mar; 14(1):1221. PubMed ID: 36869047
[TBL] [Abstract] [Full Text] [Related]
10. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
[TBL] [Abstract] [Full Text] [Related]
11. Identification of the ultrahigh-risk subgroup in neuroblastoma cases through DNA methylation analysis and its treatment exploiting cancer metabolism.
Watanabe K; Kimura S; Seki M; Isobe T; Kubota Y; Sekiguchi M; Sato-Otsubo A; Hiwatari M; Kato M; Oka A; Koh K; Sato Y; Tanaka H; Miyano S; Kawai T; Hata K; Ueno H; Nannya Y; Suzuki H; Yoshida K; Fujii Y; Nagae G; Aburatani H; Ogawa S; Takita J
Oncogene; 2022 Nov; 41(46):4994-5007. PubMed ID: 36319669
[TBL] [Abstract] [Full Text] [Related]
12. Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma treatment In Vitro and In Vivo.
Jonchere B; Williams J; Zindy F; Liu J; Robinson S; Farmer DM; Min J; Yang L; Stripay JL; Wang Y; Freeman BB; Yu J; Shelat AA; Rankovic Z; Roussel MF
Mol Cancer Ther; 2023 Jan; 22(1):37-51. PubMed ID: 36318650
[TBL] [Abstract] [Full Text] [Related]
13. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.
Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundström A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schüller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
Cancer Res; 2022 Dec; 82(24):4586-4603. PubMed ID: 36219398
[TBL] [Abstract] [Full Text] [Related]
14. n-myc Downstream-Regulated Gene 1 (NDRG1) Regulates Vascular Endothelial Growth Factor A (VEGFA) and Malignancies in Glioblastoma Multiforme (GBM).
Zhang X; Chen Q; Li Y; Chen H; Jiang Q; Hu Q
Biomed Res Int; 2022; 2022():3233004. PubMed ID: 35813230
[TBL] [Abstract] [Full Text] [Related]
15. DFMO Carbon Dots for treatment of Neuroblastoma and Bioimaging.
Paudyal S; Vallejo FA; Cilingir EK; Zhou Y; Mintz KJ; Pressman Y; Gu J; Vanni S; Graham RM; Leblanc RM
ACS Appl Bio Mater; 2022 Jul; 5(7):3300-3309. PubMed ID: 35771033
[TBL] [Abstract] [Full Text] [Related]
16. Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group.
Wieczorek A; Stefanowicz J; Hennig M; Adamkiewicz-Drozynska E; Stypinska M; Dembowska-Baginska B; Gamrot Z; Woszczyk M; Geisler J; Szczepanski T; Skoczen S; Ussowicz M; Pogorzala M; Janczar S; Balwierz W
BMC Cancer; 2022 Jun; 22(1):701. PubMed ID: 35752779
[TBL] [Abstract] [Full Text] [Related]
17. Genetic Markers as Predictors for Response to treatment and Possible Therapeutic Targets in Medulloblastoma.
Pérez-Pineda PL; Ortiz-Butrón R; Pérez-De Marcos JC; Hernández-Regino LM; Zapata-Tarrés MM; Torres-Espíndola LM
CNS Neurol Disord Drug Targets; 2023; 22(5):634-642. PubMed ID: 35579144
[TBL] [Abstract] [Full Text] [Related]
18. Ependymoma: Evaluation and Management Updates.
Rudà R; Bruno F; Pellerino A; Soffietti R
Curr Oncol Rep; 2022 Aug; 24(8):985-993. PubMed ID: 35384591
[TBL] [Abstract] [Full Text] [Related]
19. [Precision Medicine for Ependymoma].
Gomi A
No Shinkei Geka; 2022 Jan; 50(1):91-100. PubMed ID: 35169089
[TBL] [Abstract] [Full Text] [Related]
20. Regression in Early Childhood Development: An Unintended Outcome of Prolonged Hospitalization?
Dahl CM; Kroupina M; Lone DW; Greengard E; Somani A
J Pediatr Hematol Oncol; 2022 Apr; 44(3):e795-e798. PubMed ID: 35129139
[TBL] [Abstract] [Full Text] [Related]
[Next]
